Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Radiopharma pipeline builds ahead of key data

Nature Cancer volume 6, pages 1905–1908 (2025)Cite this article

This article has been updated

Investment continues as the field awaits phase 3 readouts for next-generation radioligand therapies in 2026.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 06 October 2025

    In the version of the article initially published, in the "Shielding requirement" row of Table 3, "owing to longer-wavelength gamma rays" should have read "owing to shorter-wavelength gamma rays" and has now been corrected in the HTML and PDF versions of the article.

References

  1. Senior, M. Nat. Biotechnol. 42, 1003–1008 (2024).

    Article  PubMed  CAS  Google Scholar 

  2. Kleinendorst, S. C. et al. Eur. J. Nucl. Med. Mol. Imaging https://doi.org/10.1007/s00259-025-07293-0 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  3. ITM presents positive topline phase 3 COMPETE trial data with n.c.a. 177Lu-edotreotide (ITM-11), a targeted radiopharmaceutical therapy, in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors at the ENETS 2025 conference. ITM Radiopharma https://go.nature.com/46lIJJW (2025).

  4. FDA approves Novartis radioligand therapy Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer. Novartis https://go.nature.com/4mLFaT8 (2025).

  5. Li, M. et al. Cancers 13, 3676 (2021).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Krasnovskaya, O. O. et al. Int. J. Mol. Sci. 24, 9154 (2023).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Buteau, J. et al. J. Nuclear Med. 66, 251535 (2025).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. London, UK

    Melanie Senior

Authors
  1. Melanie Senior
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Melanie Senior.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Senior, M. Radiopharma pipeline builds ahead of key data. Nat Cancer 6, 1905–1908 (2025). https://doi.org/10.1038/s43018-025-01044-8

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s43018-025-01044-8

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing